COO Nasdaq· Cooper Companies, Inc
FundamentalsNews digest Peer analysis
COO Nasdaq· Cooper Companies, Inc
Earnings report Q4 2023

COO Reports Strong Revenue Growth in Latest Quarter

Segments of revenue

COO, a leading company in the healthcare industry, reported robust revenue growth in the latest quarter. Net sales for fiscal 2023 reached $3.59 billion, a significant increase from $3.31 billion in fiscal 2022 and $2.92 billion in fiscal 2021. This represents a year-over-year growth rate of 8.4% and 22.9% respectively.


The company's strong revenue growth can be attributed to the performance of its two main segments, CooperVision and CooperSurgical. CooperVision, which specializes in contact lenses, experienced a 15% increase in operating income in fiscal 2023 compared to the previous year. This growth was primarily driven by higher net sales, partially offset by changes in operating expenses. CooperSurgical, focused on women's health, also saw an increase in net sales, although its operating income declined due to higher selling, general, and administrative (SGA) expenses and research and development (R&D) expenses.


Despite the overall positive performance, COO faced challenges in its corporate operating loss, which increased in fiscal 2023 compared to the previous year. This was mainly due to higher share-based compensation expenses.


COO experienced a significant increase in interest expense during fiscal 2023, primarily driven by higher interest rates. Additionally, the company reported other expenses of $14.9 million in fiscal 2023, which included a foreign exchange loss and other miscellaneous expenses.


COO delivered a strong performance in the latest quarter, with robust revenue growth driven by the solid performance of its CooperVision and CooperSurgical segments. The company's net sales increased by 8.4% year-over-year, reaching $3.59 billion. However, COO faced challenges in its corporate operating loss and experienced higher interest expenses. Overall, COO's strong revenue growth demonstrates its ability to capitalize on market opportunities and maintain a competitive position in the healthcare industry.

Source documents

Form 10-K  filed on Dec 08, 2023
126 pages scanned

Reference data

Company financials Q4 revenue 930M
Analyst estimates Q4 EPS beat by 0.27%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.